Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine

Houman Sotoudeh(University of Alabama at Birmingham), Omid Shafaat(Johns Hopkins University), Joshua D. Bernstock(Harvard University), Michael David Brooks(University of Alabama at Birmingham), Galal Elsayed(University of Alabama at Birmingham), Jason Chen(University of California, Los Angeles), Paul Szerip(Uber AI (United States)), Gustavo Chagoya(University of Alabama at Birmingham), Florian Geßler(Goethe University Frankfurt), Ehsan Sotoudeh(Dubai Hospital), Amir Shafaat(Arak University of Technology), Gregory K. Friedman(University of Alabama)
Frontiers in Oncology
August 14, 2019
Cited by 109Open Access
Full Text

Abstract

Purpose: Artificial intelligence (AI) has accelerated novel discoveries across multiple disciplines including medicine. Clinical medicine suffers from a lack of AI-based applications, potentially due to lack of awareness of AI methodology. Future collaboration between computer scientists and clinicians is critical to maximize the benefits of transformative technology in this field for patients. To illustrate, we describe AI-based advances in the diagnosis and management of gliomas, the most common primary central nervous system (CNS) malignancy. Methods: Presented is a succinct description of foundational concepts of AI approaches and their relevance to clinical medicine, geared toward clinicians without computer science backgrounds. We also review novel AI approaches in the diagnosis and management of glioma. Results: Novel AI approaches in gliomas have been developed to predict the grading and genomics from imaging, automate the diagnosis from histopathology, and provide insight into prognosis. Conclusion: Novel AI approaches offer acceptable performance in gliomas. Further investigation is necessary to improve the methodology and determine the full clinical utility of these novel approaches.


Related Papers

No related papers found

Powered by citation graph analysis